JUN 20, 2018 07:30 AM PDT

Keynote Presentation: Supporting Precision Medicine and Clinical Research at Scale - Challenges and Opportunities

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Director of Translational Genomics and Product Development, Institute Scientist, Broad Institute of MIT and Harvard
    Biography
      Niall J. Lennon, PhD, is Senior Director of Translational Genomics and Product Development with the Genomics Platform at the Broad Institute of MIT & Harvard. Niall has been working on NGS applications and technology development at the Broad for over 11 years. Most recently, Dr. Lennon oversaw the creation, certification and launch of a CLIA certified & CAP accredited laboratory within the Broad. He led the efforts to validate and implement a clinical Whole Exome sequencing test for both germline and somatic samples.
      Niall is currently an Adjunct Assistant Professor of Biomedical Engineering at Tufts University. Niall has received a Black Belt in Six Sigma for his work on process design and optimization. He also holds an executive certificate in Management and Leadership from the MIT Sloan School of Management. Niall earned a PhD in Pharmacology, and a BSc from University College Dublin, Ireland.

    Abstract:

    Precision medicine based on molecular profiling is moving from the realm of clinical utility studies towards standard of care. There remain, however, significant technological and implementation challenges that need to be addressed to ensure the widespread access to high complexity tests. These challenges include the provision of high quality, scalable assays that can be offered in clinically meaningful timeframes and at a cost that does not limit adoption. In addition, the computational and analytical environments must exist to host, compute, and deliver the increasingly large data sets created for each patient. There needs to be agreement on best practices and specifications for performance of secondary analysis tools (variant callers) across all classes of clinically meaningful variant categories. And, there needs to be education and training of a large network of variant review scientists, clinical geneticists, and molecular pathologists on variant interpretation and classification. This presentation will contemplate these challenges, highlight areas where progress has been made, and where more has yet to be done. 


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources